Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Aurinia Pharm Ord (AUPH)

14.6   0.97 (7.12%) 01-21 00:36
Open: 13.91 Pre. Close: 13.63
High: 14.91 Low: 13.82
Volume: 6,122,451 Market Cap: 1,843M
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 14.929 - 14.99 14.99 - 15.047
Low: 13.678 - 13.741 13.741 - 13.802
Close: 14.494 - 14.598 14.598 - 14.696

Technical analysis

as of: 2021-01-20 4:44:37 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 18.27     One year: 21.34
Support: Support1: 13.80    Support2: 12.65
Resistance: Resistance1: 15.64    Resistance2: 18.27
Pivot: 13.77
Moving Average: MA(5): 13.98     MA(20): 13.74
MA(100): 14.43     MA(250): 15.29
MACD: MACD(12,26): -0.04     Signal(9): -0.13
Stochastic oscillator: %K(14,3): 48.57     %D(3): 49.38
RSI: RSI(14): 55.90
52-week: High: 20.48  Low: 9.83  Change(%): -23.3
Average Vol(K): 3-Month: 218543  10-Days: 408956

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
AUPH has closed below upper band by 3.3%. Bollinger Bands are 16.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sat, 16 Jan 2021
The Week Ahead In Biotech: FDA To Issue Decisions On Merck And Aurinia Drug Applications - Benzinga

Thu, 17 Dec 2020
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan - Yahoo Finance

Fri, 13 Nov 2020
Aurinia Stock to Surge by 80%? This 5-Star Analyst Thinks It’s Possible - Nasdaq

Tue, 10 Nov 2020
Aurinia Pharmaceuticals: Q3 Earnings Insights - Yahoo Finance

Thu, 05 Nov 2020
Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance

Wed, 16 Sep 2020
Hedge Funds Can’t Stop Buying Aurinia Pharmaceuticals Inc (AUPH) - Yahoo Finance

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 126
Shares Float (M) 111
% Held by Insiders 9.77
% Held by Institutions 55.87
Shares Short (K) 5,220
Shares Short P. Month (K) 5,120

Stock Financials

EPS -1.410
EPS Est This Year -1.010
EPS Est Next Year -0.390
Book Value (p.s.) 3.150
Profit Margin
Operating Margin -93735.90
Return on Assets (ttm) -22.4
Return on Equity (ttm) -59.9
Qtrly Rev. Growth -87.4
Gross Profit (p.s.) -0.416
Sales Per Share 0.001
EBITDA (p.s.) -0.858
Qtrly Earnings Growth
Operating Cash Flow (M) -101
Levered Free Cash Flow (M) -61

Stock Valuations

PE Ratio -10.35
PEG Ratio
Price to Book value 4.63
Price to Sales 15754.27
Price to Cash Flow -18.32

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.